Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
granulocyte colony-stimulating factor (G-CSF)
- Development stage
- Phase 4
- Lead developer
- Amgen
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Granulocyte colony-stimulating factor (G-CSF), also known as colony-stimulating factor 3 (CSF3), is an endogenous glycoprotein cytokine that regulates the production, differentiation, and mobilization of neutrophils in the bone marrow. Recombinant G-CSF analogs, such as filgrastim and lenograstim, as well as long-acting pegylated forms like pegfilgrastim, are widely used in clinical practice. G-CSF acts by binding to and activating the colony-stimulating factor 3 receptor (CSF3R), triggering downstream JAK/STAT, MAPK, and PI3K/Akt signaling pathways. Its primary therapeutic indications include the prevention and treatment of chemotherapy-induced neutropenia, treatment of severe chronic neutropenia, and mobilization of hematopoietic stem cells into the peripheral blood for autologous or allogeneic stem cell transplantation.
- Brand names
- GranixGranocyteGranulokineLonquexNeulastaNeupogenNivestimPelmegRolvedonRyzneutaZarzio
- Other names
- CSF3CSF-3CSF 3G-CSFcolony-stimulating factor 3granulocyte colony-stimulating factorpluripoietinr-metHuG-CSFrecombinant human granulocyte colony-stimulating factor
02
Targets
CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on granulocyte colony-stimulating factor (G-CSF).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on granulocyte colony-stimulating factor (G-CSF).